ADC Therapeutics SA expected to post a loss of 40 cents a share - Earnings Preview

ADC Therapeutics SA

02/05/2025 14:26

ADC Therapeutics SA ADCT.N, ADCT.K is expected to show a fall in quarterly revenue when it reports  results on May 5 (estimated) for the period ending March 31 2025

The Epalinges Vaud-based  company is expected to report a 1.9% decrease in revenue to $17.709 million from $18.05 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for ADC Therapeutics SA is for a loss of 40 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 2.0% in the last three months. ​

Wall Street's median 12-month price target for ADC Therapeutics SA is $8.00​, above​ its last closing price of $1.43. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.44
-0.41
-0.29
Beat
29.6
Sep. 30 2024
-0.36
-0.39
-0.42
Missed
-6.3
Jun. 30 2024
-0.45
-0.46
-0.38
Beat
16.9​
Mar. 31 2024
-0.55
-0.56
-0.56
Met
-0.8
​​Dec. 31 2023
-0.48
-0.50
-1.03
Missed
-104.8
Sep. 30 2023
-0.65
-0.63
-0.58
Beat
8.5​
Jun. 30 2023
-0.35
-0.46
-0.58
Missed
-26.9
Mar. 31 2023
-0.76
-0.67
-0.74
Missed
-10.4

This summary was machine generated May 2 at 13:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)